M&A Deal Summary

LakePharma Acquires Blue Sky BioServices

On March 22, 2016, LakePharma acquired life science company Blue Sky BioServices from Ampersand Capital Partners

Acquisition Highlights
  • This is LakePharma’s 1st transaction in the Life Science sector.
  • This is LakePharma’s 1st transaction in the United States.
  • This is LakePharma’s 1st transaction in Massachusetts.

M&A Deal Summary

Date 2016-03-22
Target Blue Sky BioServices
Sector Life Science
Buyer(s) LakePharma
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition

Target

Blue Sky BioServices

Worcester, Massachusetts, United States
Blue Sky BioServices is a contract research organization (CRO) that provides gene through screen services in the pharmaceutical and biotechnology R&D market. Blue Sky BioServices was founded in 2003 and is based in Worcester, Massachusetts.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

LakePharma

San Carlos, California, United States

Category Company
Founded 2009
Sector Life Science
DESCRIPTION

LakePharma is a biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma was founded in 2009 and is based in San Carlos, California.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


DEAL STATS #
Overall 24 of 56
Sector: Life Science M&A 10 of 26
Type: Add-on Acquisition M&A Deals 17 of 39
State: Massachusetts M&A 4 of 14
Country: United States M&A 24 of 51
Year: 2016 M&A 2 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-11 GENEWIZ

South Plainfield, New Jersey, United States

GENEWIZ, Inc. is a provider of R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. GENEWIZ, Inc. was founded in 1999 and is based in South Plainfield, New Jersey.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 Magellan Biosciences

Chelmsford, Massachusetts, United States

Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Sell -